The Zacks Electronics – Testing Equipment industry has been benefiting from the rapid build-out of AI infrastructure, which is increasing demand for semiconductor manufacturing and validation equipment. Testing solutions are becoming increasingly critical for wafer fabrication, chip inspection, embedded computing validation and hardware verification. The build-out of hyperscale data centers and power infrastructure is increasing demand for electrical testing, power validation and hardware-in-the-loop simulation. Factories and logistics facilities are investing in greater automation, increasing demand for machine vision, barcode reading and automated inspection systems. The launch of AI-powered testing and inspection platforms that improve speed, accuracy and productivity has noteworthy development. Industry players like AMETEK (AME - Free Report) and Fortive (FTV - Free Report) are benefiting from this trend. However, supply chain constraints and component inflation are headwinds for industry players.
Industry Description The Zacks Electronics – Testing Equipment industry comprises companies offering advanced instruments, electronic testing equipment solutions, thermal management systems, electrical connectors, motors and various test solutions. The major end markets served by this industry are consumer, automobile, industrial, aerospace and defense, healthcare, semiconductors and communications, to name a few. Industry participants have been making technological advancements to gain traction among semiconductors, vehicles, machinery, smartphones and medical device manufacturers, who are constantly increasing their spending on electronic components.
4 Trends Shaping the Future of Electronics - Testing Equipment Industry Solid Adoption of Motion Control & Test Systems is Positive: The rising utilization of precision motion-control solutions and automatic test systems in motion-control devices and testing products, particularly in the aerospace, automation, medical and military markets, is an upside. Commercial motor and autonomous vehicles will likely continue to hike the demand for vehicle-tracking systems, fleet-management solutions and other private fleet applications, which are part of the industry’s key offerings.
Secular Growth, Niche Strength and Sustainability-Driven Demand Aids Growth: Secular growth is driven by exposure to long-term themes like automation, healthcare, aerospace, semiconductors and energy transition. Industry players operate in niche, mission-critical segments where products are essential to performance and safety. This supports strong pricing power, customer attachment and consistently high margins compared to broader industrial peers. Sustainability and energy transition trends are creating new demand for products that improve efficiency, reduce emissions and support renewable energy adoption, providing an additional long-term growth driver.
Recurring Revenues Boost Free Cash Flow Generation Ability: A meaningful portion of revenue comes from recurring streams such as aftermarket services, calibration, maintenance and spares. This improves earnings visibility and reduces volatility across cycles. Asset-light business models require relatively low capital expenditure, resulting in high free cash flow conversion. This supports shareholder returns, reinvestment and acquisition strategies.
Macroeconomic Headwinds Pose Concerns: Due to the challenging macroeconomic scenario, enterprises are reluctant to sign multi-year deals worldwide. The industry is seeing supply chain volatility, along with the negative impact of tariffs. These trends do not bode well for the industry participants.
Zacks Industry Rank Indicates Bright Prospects The Zacks Electronics – Testing Equipment industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #28 at present, which places it in the top 11% of more than 250 Zacks industries.
The group’s Zacks Industry Rank, the average of the Zacks Rank of all the member stocks, indicates bullish near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
The industry’s position in the top 50% of the Zacks-ranked industries is a result of a positive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are optimistic about this group’s earnings growth potential. The industry’s earnings estimates for 2026 have moved north by 10.8% since July 31, 2025.
Given the bullish scenario, there are a number of stocks currently worth watching. But before we present those stocks, let us look at the industry’s recent stock-market performance and the valuation picture.
Industry Outperforms S&P 500 & Sector The Zacks Electronics – Testing Equipment industry has outperformed the S&P 500 and the broader sector over the past year. The industry has climbed 31.6% over this period against the S&P 500’s appreciation of 21.2% and the broader sector’s return of 27.4%.
One-Year Price Performance
Industry's Current Valuation Based on the forward 12-month price-to-earnings ratio (P/E), a commonly used multiple for valuing the Electronics – Testing Equipment stocks, the industry is currently trading at 25.49X, higher than the S&P 500’s 20.74X and the sector’s 25.56X.
Over the past five years, the industry has traded as high as 30.91X and as low as 19.23X, with a median of 23.83X, as the chart below shows.
Forward 12-Month P/E Ratio
2 Testing Equipment Stocks to Buy AMETEK: This Zacks Rank #2 (Buy) company is benefiting from strong order growth, record backlog and acquisitions. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMETEK’s order momentum increased in the first quarter of 2026. Total orders were $2.2 billion, up 23% year over year, lifting backlog to a record $3.87 billion. AMETEK continues to supplement organic growth with bolt-on acquisitions in niche markets that extend the portfolio. In April 2026, AMETEK entered into a definitive agreement to acquire First Aviation Services, a defense and aviation MRO provider with about $80 million of annual sales that will join EMG, adding further defense aftermarket exposure. The company acquired LKC Technologies in January 2026 for $209.6 million of cash, adding ophthalmic diagnostics capabilities within EIG.
AMETEK expects 2026 sales to increase high single digits. The company expects earnings between $7.94 and $8.14 per share, suggesting 7-10% year-over-year growth.
The Zacks Consensus Estimate for 2026 earnings has increased by a penny to $8.14 per share over the past 30 days, indicating year-over-year growth of 9.56%. Shares of AMETEK have climbed 14.6% year to date.
Price & Consensus: AME
Fortive: This Zacks Rank #2 company is benefiting from steady demand across Intelligent Operating Solutions and Advanced Healthcare Solutions. Fortive's “Fortive Accelerated” strategy is gaining traction. The company reported more than 5% core revenue growth in the first quarter of 2026, with growth accelerating across both operating segments. The company highlighted continued momentum in innovation, commercial execution and recurring customer value initiatives, while reaffirming confidence in its 2026-2027 financial framework.
Fortive is benefiting from the AI infrastructure buildout through its Fluke business. The company is seeing strong customer adoption of its CertiFiber Max data center testing solution, which is also driving sales of complementary products such as power quality, battery testing and calibration equipment.
Fortive expects 2026 adjusted earnings between $2.90 and $3 per share, indicating 9% year-over-year growth at the midpoint. The Zacks Consensus Estimate for 2026 earnings has been revised a penny upward in the past 30 days to $2.97 per share, indicating year-over-year growth of 9.59%. Shares of Fortive have climbed 10.5% year to date.
California Public Employees Retirement System decreased its stake in AMETEK, Inc. (NYSE:AME – Free Report) by 7.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 401,034 shares of the technology company’s stock after selling 30,304 shares during the quarter. California Public Employees Retirement System owned approximately 0.17% of AMETEK worth $85,966,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the stock. Florida Financial Advisors LLC lifted its holdings in shares of AMETEK by 2.2% during the 4th quarter. Florida Financial Advisors LLC now owns 1,974 shares of the technology company’s stock valued at $406,000 after buying an additional 43 shares during the last quarter. Plato Investment Management Ltd raised its position in AMETEK by 0.4% during the fourth quarter. Plato Investment Management Ltd now owns 10,751 shares of the technology company’s stock valued at $2,218,000 after acquiring an additional 47 shares in the last quarter. Allegiance Financial Group Advisory Services LLC raised its position in AMETEK by 4.0% during the fourth quarter. Allegiance Financial Group Advisory Services LLC now owns 1,254 shares of the technology company’s stock valued at $257,000 after acquiring an additional 48 shares in the last quarter. Washington Trust Advisors Inc. lifted its stake in AMETEK by 6.2% in the fourth quarter. Washington Trust Advisors Inc. now owns 850 shares of the technology company’s stock valued at $175,000 after acquiring an additional 50 shares during the last quarter. Finally, Root Financial Partners LLC grew its position in AMETEK by 18.3% in the first quarter. Root Financial Partners LLC now owns 323 shares of the technology company’s stock worth $69,000 after acquiring an additional 50 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.
AMETEK Trading Down 0.1% AMETEK stock opened at $236.66 on Monday. The company has a quick ratio of 0.72, a current ratio of 1.14 and a debt-to-equity ratio of 0.10. The business has a 50 day moving average price of $231.11 and a two-hundred day moving average price of $226.52. AMETEK, Inc. has a 12 month low of $175.61 and a 12 month high of $244.71. The stock has a market cap of $54.24 billion, a price-to-earnings ratio of 35.75, a price-to-earnings-growth ratio of 3.32 and a beta of 0.99.
AMETEK (NYSE:AME – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The technology company reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.90 by $0.07. AMETEK had a return on equity of 16.63% and a net margin of 20.11%.The company had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.91 billion. During the same period in the previous year, the business earned $1.75 earnings per share. The company’s quarterly revenue was up 11.3% on a year-over-year basis. AMETEK has set its FY 2026 guidance at 7.940-8.140 EPS and its Q2 2026 guidance at 1.960-2.000 EPS. As a group, equities analysts forecast that AMETEK, Inc. will post 8.14 EPS for the current year.
AMETEK Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, June 15th were given a dividend of $0.34 per share. The ex-dividend date was Monday, June 15th. This represents a $1.36 annualized dividend and a yield of 0.6%. AMETEK’s dividend payout ratio is 20.54%.
Wall Street Analysts Forecast Growth Several research firms recently issued reports on AME. Robert W. Baird set a $244.00 price objective on shares of AMETEK in a research note on Friday, May 1st. Wall Street Zen downgraded shares of AMETEK from a “buy” rating to a “hold” rating in a research report on Sunday, May 10th. Truist Financial raised their target price on AMETEK from $275.00 to $303.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. DA Davidson reiterated a “buy” rating and set a $265.00 price target on shares of AMETEK in a research note on Monday, May 4th. Finally, Royal Bank Of Canada increased their price objective on AMETEK from $259.00 to $260.00 and gave the company an “outperform” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.29.
Check Out Our Latest Analysis on AMETEK
AMETEK Company Profile (Free Report)
AMETEK, Inc is a global manufacturer of electronic instruments and electromechanical devices that serves a broad range of industries. Headquartered in Berwyn, Pennsylvania, the company designs and produces precision instruments, electronic measurement devices, specialty sensors, and electric motors and motion control systems. Its product portfolio includes analytical and monitoring instruments, calibration equipment, power supplies, embedded electronics, and industrial motors and drives used for critical applications.
The company operates through two primary business platforms — an electronic instruments group focused on analytical, test and measurement and sensor products, and an electromechanical group that supplies motors, actuators, and related power and motion solutions.
Further Reading Five stocks we like better than AMETEK Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding AME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMETEK, Inc. (NYSE:AME – Free Report).
Receive News & Ratings for AMETEK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMETEK and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEiShares Large Cap Max Buffer Mar ETF (BATS:MMAX) CTO Sells $145,100.00 in Stock
NEXT HEADLINE »Saga (LON:SAGA) Insider Mark Watkins Purchases 276 Shares
Ness Ziona, Israel, July 17, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that on July 14, 2026, its Board of Directors (the “Board”) appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact - Earnings to be released before market opens on Tuesday, August 4, 2026 -
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) will issue its second quarter 2026 earnings release before the market opens on Tuesday, August 4, 2026.
AMETEK will webcast its second quarter 2026 investor conference call on Tuesday, August 4, 2026, beginning at 8:30 AM ET. The live audio webcast can be accessed by clicking on the Events & Presentations link in the "Investors" section of www.ametek.com. A replay of the call will also be archived on the website and will be available until the next quarterly earnings call.
Corporate Profile:
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610.889.5247
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Ametek (AME - Free Report) . This company, which is in the Zacks Electronics - Testing Equipment industry, shows potential for another earnings beat.
This maker of electronic instruments and electromechanical devices has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 3.65%.
For the most recent quarter, Ametek was expected to post earnings of $1.9 per share, but it reported $1.97 per share instead, representing a surprise of 3.68%. For the previous quarter, the consensus estimate was $1.94 per share, while it actually produced $2.01 per share, a surprise of 3.61%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for Ametek. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Ametek currently has an Earnings ESP of +0.39%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #2 (Buy) indicates that another beat is possibly around the corner.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Nes Ziona, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure today announced that a U.S. Government lab conducting quantum computing programs is actively operating the Company’s AME system. The operational use places the Company’s technology inside a U.S. federal quantum and advanced-microelectronics development environment, providing the lab with direct access to the unique capabilities enabled by the Company’s AME platform.
The lab is one of the most prominent U.S. government research environments focused on national security, applying advanced science and engineering to help identify, deter, defeat and mitigate threats to the United States and its allies. Within this environment, the lab conducts quantum computing programs focused on moving quantum technologies from experimental research toward practical, measurable and engineered systems. This includes fabrication and characterization, integrated control technologies, mathematical modeling and experimental testing on real-world quantum systems.
As quantum systems advance toward larger and more complex architectures, they require new approaches for manufacturing high-density interconnects, advanced packaging structures, integrated materials, RF/microwave pathways and application-specific electronic components. The operational use of QTREX’s AME system inside this environment positions the Company’s technology directly within the infrastructure layer required to support quantum hardware development.
"The current U.S. administration has made it unequivocally clear that quantum computing and advanced microelectronics are critical, heavily funded national security priorities," said Dagi Ben-Noon, CEO of QTREX. "Having our AME system actively operating inside a federal lab directly aligns QTREX with these massive strategic initiatives and positions us at the heart of the infrastructure required to secure U.S. quantum leadership."
QTREX views this operational deployment as a strategic platform for deeper technical engagement, defined use cases and broader commercial expansion. Amid an accelerating wave of federal investment in sovereign quantum infrastructure, direct exposure to AME capabilities within this national security lab environment paves the way for future application-specific development tailored to sensitive, mission-critical and classified defense applications.
About QTREX Quantum
QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business.
For more information, please visit: QTREX
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that having its AME system actively operating inside a federal lab directly aligns QTREX with these strategic initiatives, positioning it at the heart of the infrastructure required to secure U.S. quantum leadership, its view that this operational deployment is a strategic platform for deeper technical engagement, defined use cases and broader commercial expansion, an accelerating wave of federal investment in sovereign quantum infrastructure, direct exposure to AME capabilities within this national security lab environment paves the way for future application-specific development tailored to sensitive, mission-critical and classified defense applications. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements. More detailed information about the risks and uncertainties affecting the Company is contained under “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission.
Company Contact
QTREX Quantum
Email: [email protected]
Phone: +972-9-9664487
On June 17, 2026, we present a DCF analysis for AMETEK Inc (AME), a company that has shown notable price performance with a year-to-date increase of 13.3% and a
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that it has entered into a definitive agreement to acquire First Aviation Services, a leading provider of highly engineered, mission-critical defense and aviation maintenance, repair and overhaul (MRO) services and a manufacturer of related proprietary components.
First Aviation's MRO capabilities include advanced electronics, rotor blades and assemblies, propellers, landing gear, and flight controls. In addition, First Aviation specializes in designing, engineering, and manufacturing critical parts across a wide range of defense and aviation platforms.
"First Aviation is a strong strategic fit with our MRO platform, providing attractive market expansion opportunities and broadening the scope of our component MRO services," said David A. Zapico, AMETEK Chairman and Chief Executive Officer. "Their proprietary products and services further broaden our differentiated products serving mission critical applications. We look forward to leveraging our respective operating, engineering and distribution strengths to continue to grow our combined capabilities."
First Aviation Services has annual sales of approximately $80 million and operates six centers of excellence throughout the U.S. The transaction is subject to customary closing conditions, including applicable regulatory approvals.
Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610-889-5247
Ametek (AME) came out with quarterly earnings of $1.97 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.75 per share a year ago.
While the top- and bottom-line numbers for Ametek (AME) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that it has entered into a definitive agreement to acquire a portfolio of instrumentation businesses from Indicor, LLC ("Indicor Instrumentation") in an all‑cash transaction valued at approximately $5.0 billion.
Indicor Instrumentation is a group of leading businesses that design and manufacture mission critical solutions for demanding industrial and scientific applications. Its products serve customers across attractive end markets that align closely with AMETEK's existing portfolio and generate a substantial base of recurring revenue from consumables, services, and aftermarket support.
"Indicor is an exceptional fit for AMETEK," said David A. Zapico, AMETEK Chairman and Chief Executive Officer. "In a single transaction, we are adding a high-quality group of businesses with differentiated technologies, complementary market positions, and attractive growth prospects. We see meaningful potential to create value through integration into AMETEK's operating model."
Indicor Instrumentation generates approximately $1.1 billion in annual sales and has profitability levels consistent with AMETEK. Following closing of the transaction, the businesses will be integrated into AMETEK's Electronic Instruments Group (EIG) and Electromechanical Group (EMG) based on product offerings and market alignment.
AMETEK plans to fund the acquisition through borrowings under its existing credit facility and new debt issuance. The transaction is subject to customary closing conditions, including applicable regulatory approvals, and is expected to close in the second half of 2026.
AMETEK will host a conference call to discuss the acquisition at 8:00 a.m. Eastern Time on May 6, 2026. The live audio webcast will be available and later archived in the Investors section of www.ametek.com.
Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610-889-5247
3D Printing is reshaping industries with faster production and lower costs, drawing investor interest. Stocks like NVDA, AME, CRS and ATI offer strong growth potential.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- The Board of Directors of AMETEK, Inc. (NYSE: AME) declared a regular quarterly dividend of $0.34 per share for the second quarter ending June 30, 2026.
This second quarter dividend is payable June 30, 2026 to shareholders of record as of June 15, 2026.
Corporate Profile:
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610.889.5247
Research Tools All Access Research Tools Live News Feed Momentum Alerts Idea Engine Export Data (CSV) See All Research Tools My MarketBeat My Portfolio My Newsletter My Account Calculators Dividend Calculator Dividend Yield Calculator Market Cap Calculator Options Profit Calculator Stock Average Calculator Stock Split Calculator Stock Profit Calculator Stock Screeners Stock Screener ETF Screener Stock Ratings Screener Dividend Screener Earnings Screener Updated Insider Trades Screener Updated Trending Stocks Trending MarketBeat Stocks Trending Media Mentions High Media Sentiment Stocks Premium Reports The Rise of the Robots NewBeginner's Guide to 5G Stocks New10 Stocks Set to Soar in 2026 NewEssential Insights: Almost Everything You Need to Know About the EV Market New7 AI Stocks to Invest In 10 Best High-Yield Dividend Stocks Hottest IPOs 7 Best Space Stocks Premium Articles Financial Calendars Calendars and Market Data Market Data All Market Data and Financial Calendars Analyst Ratings Recent Analyst Ratings Stock Ratings Screener Top-Rated Stocks Lowest-Rated Stocks Top-Rated Analysts Top-Rated Brokerages Most-Upgraded Stocks Free Ratings Newsletter Congressional Data Recent Trades Most Bought Stocks Members of Congress Corporate Events Corporate Buybacks Initial Public Offerings (IPOs) IPO Lockup Expirations SEC Filings Stock Splits Dividends Today's Announcements Ex-Dividend Calendar Dividend Increases Dividend Achievers Best Dividend Stocks High-Yield Dividend Stocks Top-Rated Dividend Stocks Dividend Screener Free Dividend Newsletter Earnings Today's Announcements Tomorrow's Announcements Next Week's Announcements Upcoming Earnings Calls Earnings Call Transcripts Earnings Screener Updated Upcoming FDA Calendar Recent FDA Calendar Insider Trades Today's Insider Trades Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Updated Insider Trades Newsletter Stock Market Holidays Cryptocurrencies All Cryptocurrencies Cryptocurrency Headlines Cryptocurrency Newsletter Gainers & Decliners Percentage Gainers Percentage Decliners Pre-Market Movers After Hours Movers Breakout Stocks High & Low P/E High P/E Stocks Low P/E Stocks Highs & Lows 52-Week Highs 52-Week Lows Most Active Most Active Stocks Most Volatile Stocks Unusual Trading Volume Trading Halts Options Unusual Call Volume Unusual Put Volume Sector Performance Short Interest Largest Short Positions Short Interest Increases Short Interest Decreases Stock Lists All Stock Lists Stocks by Interest 5G Stocks Blue Chip Stocks Biotech Stocks FAANG Stocks Gold Stocks Large Cap Stocks Marijuana Stocks Oil Stocks REITs Russell 2000 Stocks Small Cap Stocks Warren Buffett Stocks Low Priced Stocks Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $5 Penny Stocks Most Active Penny Stocks Most Popular Penny Stocks Top Penny Stocks Today Stocks by Exchange NYSE Stocks NASDAQ Stocks OTCMKTS Stocks TSX Stocks LSE Stocks Stocks by Sector Automotive Stocks Aerospace Stocks Basic Materials Stocks Business Services Stocks Consumer Discretionary Stocks Consumer Staples Stocks Construction Stocks Energy Stocks Finance Stocks Industrial Stocks Manufacturing Stocks Medical Stocks Real Estate Stocks Retail Stocks Technology Stocks Transportation Stocks Utilities Stocks Technical Indicators Death Cross Stocks Golden Cross Stocks RSI Overbought Stocks RSI Oversold Stocks Stock Comparisons Premium Stock Lists Top MarketRank™ Stocks Top-Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Headlines News & Analysis AI Analyst Ratings Biotech Dividends Earnings Electric Vehicles ETFs Insider Trades IPOs Macro Markets Mergers & Acquisitions Rare Earth Minerals Semiconductors Short Interest Space MarketBeat TV Stock Ideas Get trade ideas with thorough analysis of stocks that are poised to move.
Financial Terms Learn investing concepts from our glossary of over 200 financial terms.
Research Surveys Gain valuable insights into financial trends and economic impacts from consumer research studies.
Real-Time News Feed View real-time investing headlines and stock market news for your watchlist or the broader market.
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 323
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
Research Tools All Access Research Tools Live News Feed Momentum Alerts Idea Engine Export Data (CSV) See All Research Tools My MarketBeat My Portfolio My Newsletter My Account Calculators Dividend Calculator Dividend Yield Calculator Market Cap Calculator Options Profit Calculator Stock Average Calculator Stock Split Calculator Stock Profit Calculator Stock Screeners Stock Screener ETF Screener Stock Ratings Screener Dividend Screener Earnings Screener Updated Insider Trades Screener Updated Trending Stocks Trending MarketBeat Stocks Trending Media Mentions High Media Sentiment Stocks Premium Reports The Rise of the Robots NewBeginner's Guide to 5G Stocks New10 Stocks Set to Soar in 2026 NewEssential Insights: Almost Everything You Need to Know About the EV Market New7 AI Stocks to Invest In 10 Best High-Yield Dividend Stocks Hottest IPOs 7 Best Space Stocks Premium Articles Financial Calendars Calendars and Market Data Market Data All Market Data and Financial Calendars Analyst Ratings Recent Analyst Ratings Stock Ratings Screener Top-Rated Stocks Lowest-Rated Stocks Top-Rated Analysts Top-Rated Brokerages Most-Upgraded Stocks Free Ratings Newsletter Congressional Data Recent Trades Most Bought Stocks Members of Congress Corporate Events Corporate Buybacks Initial Public Offerings (IPOs) IPO Lockup Expirations SEC Filings Stock Splits Dividends Today's Announcements Ex-Dividend Calendar Dividend Increases Dividend Achievers Best Dividend Stocks High-Yield Dividend Stocks Top-Rated Dividend Stocks Dividend Screener Free Dividend Newsletter Earnings Today's Announcements Tomorrow's Announcements Next Week's Announcements Upcoming Earnings Calls Earnings Call Transcripts Earnings Screener Updated Upcoming FDA Calendar Recent FDA Calendar Insider Trades Today's Insider Trades Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Updated Insider Trades Newsletter Stock Market Holidays Cryptocurrencies All Cryptocurrencies Cryptocurrency Headlines Cryptocurrency Newsletter Gainers & Decliners Percentage Gainers Percentage Decliners Pre-Market Movers After Hours Movers Breakout Stocks High & Low P/E High P/E Stocks Low P/E Stocks Highs & Lows 52-Week Highs 52-Week Lows Most Active Most Active Stocks Most Volatile Stocks Unusual Trading Volume Trading Halts Options Unusual Call Volume Unusual Put Volume Sector Performance Short Interest Largest Short Positions Short Interest Increases Short Interest Decreases Stock Lists All Stock Lists Stocks by Interest 5G Stocks Blue Chip Stocks Biotech Stocks FAANG Stocks Gold Stocks Large Cap Stocks Marijuana Stocks Oil Stocks REITs Russell 2000 Stocks Small Cap Stocks Warren Buffett Stocks Low Priced Stocks Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $5 Penny Stocks Most Active Penny Stocks Most Popular Penny Stocks Top Penny Stocks Today Stocks by Exchange NYSE Stocks NASDAQ Stocks OTCMKTS Stocks TSX Stocks LSE Stocks Stocks by Sector Automotive Stocks Aerospace Stocks Basic Materials Stocks Business Services Stocks Consumer Discretionary Stocks Consumer Staples Stocks Construction Stocks Energy Stocks Finance Stocks Industrial Stocks Manufacturing Stocks Medical Stocks Real Estate Stocks Retail Stocks Technology Stocks Transportation Stocks Utilities Stocks Technical Indicators Death Cross Stocks Golden Cross Stocks RSI Overbought Stocks RSI Oversold Stocks Stock Comparisons Premium Stock Lists Top MarketRank™ Stocks Top-Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Headlines News & Analysis AI Analyst Ratings Biotech Dividends Earnings Electric Vehicles ETFs Insider Trades IPOs Macro Markets Mergers & Acquisitions Rare Earth Minerals Semiconductors Short Interest Space MarketBeat TV Stock Ideas Get trade ideas with thorough analysis of stocks that are poised to move.
Financial Terms Learn investing concepts from our glossary of over 200 financial terms.
Research Surveys Gain valuable insights into financial trends and economic impacts from consumer research studies.
Real-Time News Feed View real-time investing headlines and stock market news for your watchlist or the broader market.
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 323
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
Ametek (AME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ametek, Inc. is positioned for durable growth, leveraging megatrends in aerospace & defense, semiconductors, and data centers. Recent acquisitions—First Aviation and Indicor ($5B)—significantly expand AME's aerospace, defense, and instrumentation capabilities, with value accretion expected from late 2026. I reiterate my buy rating on AME stock with a $272/share price target at 20.23x eFY28 EV/aEBITDA, citing robust market dynamics and strategic expansion.
, /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that it has completed its acquisition of First Aviation Services, a leading provider of highly engineered defense and aviation maintenance, repair and overhaul (MRO) services and a manufacturer of related proprietary components.
"We are excited to welcome the First Aviation team to AMETEK," said David A. Zapico, AMETEK Chairman and Chief Executive Officer. "First Aviation is an excellent strategic fit with our existing MRO business, creating attractive opportunities for market expansion and added scale in support of mission-critical aerospace and defense applications. Their proprietary products and services nicely complement AMETEK's capabilities and strengthen our position across attractive platforms."
First Aviation's MRO capabilities include advanced electronics, rotor blades and assemblies, propellers, landing gear, and flight controls. In addition, the company specializes in the design, engineering, and manufacturing of critical parts across a wide range of defense and aviation platforms.
First Aviation Services generates approximately $80 million in annual revenue and operates six centers of excellence throughout the U.S. They join AMETEK as part of its Electromechanical Group (EMG).
Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.
Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
[email protected]
Phone: 610-889-5247
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois taking place May 29 – June 2, 2026.
Key data that will be presented include:
Abstract #3077 validating the use of Guardant360 Liquid CDx as a companion diagnostic for therapy selection and comprehensive pan-cancer tumor profiling in routine oncology practice. Findings led to recent FDA approval of the IVD assay, marking the world’s largest FDA-approved liquid biopsy panel, demonstrating how incorporating both genomic and epigenomic signals for variant detection produces strong analytical sensitivity, accuracy, and specificity across clinically relevant alterations. Abstract #3070 revealing the potential of Guardant360 Liquid in expanding access to targeted ALK inhibitor therapy and getting the right treatment to lung patients faster. Demonstrating advanced detection missed by standard genomic methods, the analysis demonstrated improved detection of actionable ALK fusions in non-small cell lung cancer (NSCLC) while maintaining high specificity by identifying additional ALK fusion-positive cases. Abstract #TPS10632 evaluating longitudinal performance of the Shield blood test for primary colorectal cancer screening in its intended use population, building off the strong performance in the prospective, observational ECLIPSE study that led to FDA approval. “Our presence at this year’s ASCO reflects the power of liquid biopsy tests to provide oncologists with actionable insights to more effectively treat patients in a faster amount of time,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Guardant’s Smart Platform, an AI-enabled multiomic technology platform behind our next generation of cancer tests, is fueling the entire portfolio and supporting new clinical applications across the cancer care continuum.”
Key Guardant Health and collaborator presentations at ASCO 2026
Presentation
Title
Time / Location
8502
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study
May 29, 2026 / 1:00 - 4:00 PM CDT
3525 / 279
A deep learning approach to quantify tumor microenvironment features associated with postoperative ctDNA status and outcomes in a phase III FOLFOX-based adjuvant colon cancer trial (N0147; Alliance)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3546 / 313
A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in NeoRAS wild-type metastatic colorectal cancer patients (C-PROWESS)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3572 / 339
Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3659 / 426
Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4050 / 33
Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA)
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4159 / 142
First-line GemCis ± immunotherapy vs FGFR inhibition in ctDNA-detected FGFR2 fusion-positive advanced cholangiocarcinoma: a real-world analysis
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4161 / 144
Real-world analysis of epigenomic molecular tumor-type prediction for biliary tract cancer in CUP
May 30, 2026 / 9:00 AM - 12:00 PM CDT
4238 / 221
Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy
May 30, 2026 / 9:00 AM - 12:00 PM CDT
3051 / 188
Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME)
May 30, 2026 / 1:30 - 4:30 PM CDT
3052 / 189
Tissue-free minimal residual disease evaluation and clinical utility in early breast cancer: a real-world study
May 30, 2026 / 1:30 - 4:30 PM CDT
3070 / 207
Cell-free DNA methylation profile-based fusion epigenotyping to enhance ALK fusion detection in NSCLC patients
May 30, 2026 / 1:30 - 4:30 PM CDT
3077 / 214
Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling
May 30, 2026 / 1:30 - 4:30 PM CDT
3105 / 242
Phase II basket trial of brigatinib for ALK fusion–positive solid tumors: ALLBREAK trial (WJOG15221M)
May 30, 2026 / 1:30 - 4:30 PM CDT
1031 / 145
Concordance between liquid and tissue biopsy in participants with newly diagnosed recurrent breast cancer
June 1, 2026 / 1:30 - 4:30 PM CDT
1095 / 209
Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i)
June 1, 2026 / 1:30 - 4:30 PM CDT
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2026 can be found on the ASCO website.
About Guardant360® Liquid CDx
The largest FDA-approved liquid biopsy, Guardant360 Liquid CDx is the only FDA-approved liquid biopsy test integrating genomic and epigenomic data for comprehensive insights. Guardant360 Liquid CDx is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer. It is also the only FDA-approved companion diagnostic for targeted therapy in advanced breast cancer patients with ESR1 mutations. The test is broadly covered by Medicare and commercial insurers, representing over 300 million lives.
About Guardant360 Liquid
Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.
About Guardant Reveal
Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.
The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsyshowed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.
About Shield
Shield is a methylation partitioning cell-free DNA (mp-cfDNA) non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260528810245/en/
Nes Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that it received a purchase order from a Fortune 500 multinational company for an AME system and related materials. The customer is headquartered in the United States, and the AME system will be delivered to one of the customer’s sites outside the United States.
QTREX’s AME system is designed to provide the customer a unique capability that cannot be achieved through conventional technologies: the ability to create intricate structures with advanced materials and customized architectures in a single workflow. This capability is designed to enable higher complexity and a path toward applications where traditional manufacturing reaches its physical limits.
The order expands QTREX’s commercial AME footprint with a global enterprise customer and reinforces the Company’s position as an advanced AME platform for demanding technology environments and is expected to contribute to the Company’s upcoming financial results, further strengthening QTREX’s growing AME commercial activity.
"Conventional manufacturing is reaching its limits in advanced electronics," said Dagi Ben-Noon, CEO of QTREX. "Our AME platform provides capabilities that conventional technologies simply cannot replicate, and that advantage is most visible in quantum connectivity, where the density, materials integration and design freedom required for scale cannot be achieved any other way. Together with our recently announced orders, we are establishing a commercial revenue base that already exceeds the most recently reported annual revenues of certain publicly traded quantum computing companies.”
The Company is actively engaging with additional prospective tier-1 customers and expects to provide further updates as its AME commercial pipeline and quantum infrastructure programs continue to advance.
About QTREX Quantum
QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business. For more information, please visit: www.q-trex.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the benefits of its AME products, that the order expands its commercial AME footprint and reinforces its position as an advanced AME platform for demanding technology environments and further strengthening its growing AME commercial activity and that it is expected to contribute to the Company’s upcoming financial results, that its AME platform provides capabilities it believes conventional technologies simply cannot replicate, that advantage in its AME platform is most visible in quantum connectivity, that it is establishing a revenue base, that it is engaging with additional prospective tier-1 customers and that it expects to provide further updates as its AME commercial pipeline and quantum infrastructure programs continue to advance. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.
Company Contact
QTREX Quantum
Email: [email protected]
Phone: +972-9-9664485
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk [email protected]
Nes Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that Mr. Tal Parnas, Chairman of the Company’s Board of Directors, and Mr. Yoav Rozanovich, the Company’s Chief Business Officer, will be in Boston, Massachusetts during Quantum.Tech World 2026 on June 25–26, 2026, to present functional AME-based monolithic connectivity components engineered for quantum computing systems.
QTREX will conduct private, invitation-only meetings with industry leaders, research institutions and strategic partners in a dedicated meeting suite adjacent to the conference venue. Meetings will be scheduled in advance through Mr. Yoav Rozanovich.
The Company will present fabricated, functional monolithic connectivity components produced using its proprietary AME platform components, specifically engineered to address cryogenic interconnect challenges in superconducting quantum systems. These components demonstrate high-density signal routing, advanced dielectric materials integration and complex 3D architectures designed for scalable quantum hardware operating under extreme cryogenic conditions. QTREX is among a small number of companies worldwide with demonstrated capability to additively manufacture such components at this level of technical specification.
Quantum.Tech World 2026 is among the foremost global forums for the commercialization of quantum technologies, bringing together leading quantum hardware developers, systems integrators, enterprise adopters, government stakeholders and research institutions. QTREX’s participation reflects the Company’s position at the hardware frontier of quantum computing infrastructure, where the interconnect challenges that constrain scalability are now being addressed through physical, manufacturable components.
Industry participants and potential partners interested in scheduling a private meeting with QTREX during Quantum.Tech World 2026 may contact:
Mr. Yoav Rozanovich
Chief Business Officer, QTREX Quantum Ltd.
Email: [email protected]
About QTREX Quantum
QTREX Quantum Ltd. (Nasdaq: QTEX) is a technology company focused on advanced connectivity and electronics manufacturing solutions for next-generation hardware markets. Following its acquisition of the AME platform, the Company is developing high-density, thermally optimized quantum connectivity solutions for dilution cryostats and advancing AME applications for defense, aerospace, missile, space, and other mission-critical environments. The Company also continues to advance its medical technology portfolio, including respiratory support and blood monitoring platforms, while actively working to monetize certain parts of the medical business. For more information, please visit: www.q-trex.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the benefits and advantages of its products and that QTREX’s participation at Quantum.Tech World 2026 reflects the Company’s position at the hardware frontier of quantum computing infrastructure. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.
Company Contact
QTREX Quantum
Email: [email protected]
Phone: +972-9-9664485
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk [email protected]
